Tarlatamab

Therapeutic indications

Tarlatamab is indicated for:

Extensive stage small cell lung cancer

Population group: only adults (18 years old or older)

Tarlatamab is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1 mg once on Cycle 1 Day 1 and 10 mg on Cycle 1 Day 8 and Day 15, and thereafter 10 mg every 2 weeks until disease progression or unacceptable toxicity

Contraindications

Tarlatamab is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.